Daklinza treatment regimen Subscription
Daklinza (daclatasvir; Bristol-Myers Squibb) can now be used for 12 weeks, rather than 24 weeks, in combination with sofosbuvir to treat patients with chronic hepatitis C genotype 3.
Increased blood pressure with DianetteSubscription
The summary of product characteristics for Dianette (cyproterone acetate and ethinylestradiol; Bayer) now includes increased blood pressure as an adverse effect.
Caneston Bifonazole interaction with warfarinSubscription
The summary of product characteristics for Canesten Bifonazole Once Daily 1% w/w Cream (Bayer) now warns of a potential interaction with warfarin. Limited data suggests that an interaction between topical bifonazole and warfarin may be possible, leading to increases in INR [international normalised ratio]. If bifonazole is used in a patient on warfarin therapy they should be appropriately monitored. Closer monitoring may be ...
Levemir (insulin detemir; Novo Nordisk) is indicated for treatment of diabetes mellitus in adults, adolescents and children aged one year and over. It was previously licensed for children aged over two years.
Edoxaban and vedolizumab recommended by NICESubscription
The National Institute for Health and Care Excellence has recommended edoxaban (Lixiana; Daiichi Sankyo) as an option for treating and preventing recurrent deep vein thrombosis or pulmonary embolism. Edoxaban is an oral anticoagulant that directly inhibits factor X (factor Xa), which is a key component in the formation of blood clots. In addition, vedolizumab (Entyvio; Takeda) has been recommended as a possible option for adults with moderate to severe ...
August 2015: SMC decisionsSubscription
The Scottish Medicines Consortium (SMC) has accepted the following medicines for NHS Scotland for particular indications: darunavir cobicistat (Rezolsta; Janssen-Cilag); palonosetron (Aloxi; Chugai); tiotropium (Spiriva Respimat; Boehringer Ingelheim). Tedizolid phosphate (Sivextro; Merck Sharp & Dohme) has been accepted for restricted use and eribulin (Halaven; Eisai) and enzalutamide (Xtandi; Astellas) have not been accepted for use.
Harvoni approved in WalesSubscription
Harvoni (ledipasvir, sofosbuvir; Gilead) has been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG) to treat adults infected with chronic hepatitis C virus genotypes 1 and 4. It is approved as a 12-week course for patients without cirrhosis or compensated cirrhosis. See the AWMSG website for full details of restrictions.
Antepsin out of stockSubscription
Antepsin (sucralfate; Chugai Pharma) 1g/5ml oral suspension and Antepsin 1g tablets are out of stock. On account of a manufacturing problem, it is unlikely that supply will be resumed until the end of 2015. An alternative supply of sucralfate tablets may be available from IDIS Pharma.
Pharmacy Management accredited by RPS FacultySubscription
The Royal Pharmaceutical Society (RPS) Faculty has accredited Pharmacy Management’s training programme, ‘Clinical leadership in pharmacy’. The organisation has also been accredited by the RPS Faculty as a training provider. More information can be found on Pharmacy Management’s website.
PHE breast cancer campaignSubscription
Public Health England has launched a national campaign to raise awareness of the risk and symptoms of breast cancer in older women. A briefing has been created for community pharmacy teams that gives advice on how to approach the topic with patients and gives details of where to order free materials for the campaign, which runs until 6 September 2015. This can
New British Pharmacopeia websiteSubscription
The websites of the British Pharmacopeia, pharmacopoeia.co.uk and pharmacopoeia.com (previously pharmacopoeia.gov.uk) have been brought together into one integrated website. The new website is available at: www.pharmacopoeia.com.
Flu vaccination resourcesSubscription
The Pharmaceutical Services Negotiating Committee (PSNC) has published several new resources to help contractors and local pharmaceutical committees with the community pharmacy flu vaccination service. The resources contain statistics and facts to help demonstrate the benefit of the service to GPs and patients. The ...
Audit on OTC medicines supplySubscription
Community pharmacists are invited to participate in a practice-based audit on the reasons for non-supply of requested over-the-counter medicines to patients. The audit, organised by Pharmacy Voice, is open to all members of the Association of Independent Multiple Pharmacies, the Company Chemists’ Association and National Pharmacy Association, and must take place for one week between 1 August and 30 November 2015.
Alcohol-related liver disease surveySubscription
The James Lind Alliance (JLA) — a non profit-making initiative that brings together patients, carers and clinicians — is conducting a survey on alcohol-related liver disease (ARLD). The survey will help create a ‘top ten’ list of questions around ARLD that should be priorities for researchers. JLA would like the input of community pharmacists. The survey can be accessed from the ‘Priority ...
Consultation on myeloma careSubscription
The National Institute for Health and Care Excellence (NICE) has published draft guidance for consultation on the care of adults suffering from myeloma. It complements existing NICE guidance on the drug treatment of myeloma. Views on the draft guideline can be submitted until 1 October 2015. More information can be found on the NICE website.
The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending daclatasvir (Daklinza; Bristol Myers-Squibb),
The National Institute for Health and Care Excellence (NICE) has published two pieces of draft guidance that will update previous recommendations on immunosuppressive therapy for kidney transplantation in adults and
NICE consults on olaparib Subscription
The National Institute for Health and Care Excellence (NICE) has issued draft guidance for public consultation on the use of olaparib (Lynparza; AstraZeneca) for the treatment of ovarian, fallopian tube and peritoneal cancer in patients with either the BRCA1 or BRCA2 gene mutations. The preliminary guidance does not recommend the drug because the price is too high. NICE has requested further estimates of cost-effectiveness from the manufacturer. The draft guidance can be found on the ...